ELI LILLY CO

📅 Upcoming

🕒 Recent(90d)

News

• GSK restructure will hit home, impacting 'limited' UK roles
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 2h ago
• STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
  Missouri attorney general warned Eli Lilly to discontinue requiring hospitals to provide claims data to receive discounted medicines under 340B program
  stat · 2h ago
• STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
  Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.
  stat · 2h ago
• Lilly shuffles business structure; Novartis writes off part of Avidity deal
  Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.
  biopharma_dive · 3h ago
• Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
  Eli Lilly’s next-gen weight loss drug retatrutide soundly beat Novo’s approved medicine Ozempic in weight loss and blood sugar reduction, padding the case for a regulatory application that’s expect…
  biospace · 3h ago
• Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes
  Eli Lilly’s retatrutide, the incretin shot that has already proven its effectiveness against other assets on a cross-trial basis, has cemented its utility in a head-to-head trial, albeit in diabete…
  endpoints · 5h ago
• STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
  Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.
  stat · 5h ago
• Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
  Eli Lilly’s triple-G drug candidate retatrutide has beaten Novo’s Ozempic in a head-to-head phase 3 trial, driving deeper reductions in blood sugar and body weight across the 80-week study.
  fiercebiotech · 8h ago
• 5 new drug launches that defied industry expectations
  A clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.
  biospace · 12h ago
• Big Pharma is ready to strike, with J&J most likely to buy: Leerink
  The largest pharmas have a collective $188 billion in firepower to spend on M&A transactions, with all but one signaling a desire to execute, according to a new analysis from Leerink Partners.
  biospace · 12h ago